Downstream characterization of anti-TNF-? single chain variable fragment antibodies
Date
2012Author
Abdolalizadeh, J
Nouri, M
Zolbanin, JM
Baradaran, B
Barzegari, A
Omidi, Y
Metadata
Show full item recordAbstract
Using phage display technology (PDT), we have recently isolated single-chain variable fragment (scFv) antibodies (Ab) against some pivotal molecular markers involved in malignancies and systemic inflammation including human tumor necrosis factor-alpha (TNF-?, GI:367465798). Downstream purification and characterization of scFv antibodies is a challenging issue, which may impose substantial impacts on quality of the final product(s). Of various purification methods, affinity chromatography has widely been used in the pharmaceutical grade downstream processing (PGDP) of proteins (e.g., monoclonal antibody (mAb) and scFvs). To pursue an optimized PGDP, in the current study, we have capitalized PDT for upstream selection of anti-TNF-? scFvs and protein A affinity chromatography (PAAC) for downstream extraction and purification of the scFvs from the crude medium secreted and periplasmic fractions of HB2151 cells. The versatility of the PDT selection was validated using SDS-PAGE electrophoresis, western blot, dot blot, ELISA and fluorescence microscopy. SDS-PAGE western blot analyses displayed a 17 kDa scFv with high purity (> 98%), while dot blot and ELISA analyses showed high specificity and binding affinity of the purified scFv antibody fragments toward human TNF-? at nM range. Fluorescence microscopy further confirmed detection of TNF-? in Raji B lymphoblast cells. Finally, based on our findings, we believe that these PDT selected and PAAC processed scFvs may be used as targeting and/or therapy agent for TNF-? mediated diseases. Further, to increase the production yield, downstream purification techniques need to be optimized for the large scale production of scFv antibodies. é 2012 - IOS Press and the authors. All rights reserved.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Target therapy of cancer: Implementation of monoclonal antibodies and nanobodies
Majidi, J; Barar, J; Baradaran, B; Abdolalizadeh, J; Omidi, Y (2009)In the past decades, the mainstay of systemic therapy for solid and haematological malignancies was chemotherapy; nevertheless this modality has the drawbacks such as drug resistance and eliciting sever cytotoxicity in the ... -
Antibody humanization methods for development of therapeutic applications
Ahmadzadeh, V; Farajnia, S; Feizi, MAH; Nejad, RAK (2014)Recombinant antibody technologies are rapidly becoming available and showing considerable clinical success. However, the immunogenicity of murine-derived monoclonal antibodies is restrictive in cancer immunotherapy. Humanized ... -
A novel monoclonal antibody against a synthetic peptide from ?-actin can react with its corresponding protein
Amini, N; Bayat, A-A; Zarei, O; Hadavi, R; Mahmoudian, J; Mahmoudi, AR; Darzi, M; Rabbani, H; Jeddi-Tehrani, M (2015)Actin is one of the most widely studied structural and multifunctional housekeeping proteins in eukaryotic cells with important roles in many cell functions. Antibodies against ?-actin and other housekeeping gene-encoded ...